Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma (ABUS)
:ABUS
Holding ABUS?
Track your performance easily
ABUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $4.73
Previous CloseN/A
Volume149.14K
Average Volume (3M)856.72K
Market Cap
$610.16M
Enterprise Value$606.61M
Total Cash (Recent Filing)$130.56M
Total Debt (Recent Filing)$12.00M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Feb 27, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,680
10 Day Avg. Volume841,164
30 Day Avg. Volume856,718
Standard Deviation0.25
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)92.19
Price to Cash Flow (P/CF)-7.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue89.97
Enterprise Value/Gross Profit33.44
Enterprise Value/Ebitda-8.13
Forecast
1Y Price Target
$4.75Price Target Upside44.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma Highlights Hepatitis B Treatment Advances
PremiumCompany Announcements
Arbutus Biopharma’s Promising cHBV Treatment Results
PremiumCompany Announcements
Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash runway guidance is extended into 1Q28, providing a longer financial cushion for the company.
Innovative ApproachArbutus's RNAi + interferon approach to treating CHB is considered a viable fast-to-market path.
Treatment EfficacyThe combination of imdusiran and pegylated interferon alfa-2a achieved undetectable HBsAg levels in a significant number of patients, which supports the potential for a functional cure.
Bears Say
Earnings OutlookNo change to outlook on earnings.
LitigationLNP litigation process continues, with ongoing legal challenges against Pfizer/BioNTech and Moderna.
Treatment StrategyKOL commentary at the meeting was mixed, with some saying that PEG-IFN needs to be brought back into the treatment regimen in the U.S., others saying they do not and will not use it.
---
Ownership Overview
1.90% Insiders
10.23% Mutual Funds
0.04% Other Institutional Investors
77.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma’s price range in the past 12 months?
Arbutus Biopharma lowest stock price was $2.22 and its highest was $4.72 in the past 12 months.
What is Arbutus Biopharma’s market cap?
Arbutus Biopharma’s market cap is $610.16M.
When is Arbutus Biopharma’s upcoming earnings report date?
Arbutus Biopharma’s upcoming earnings report date is Feb 27, 2025 which is in 40 days.
How were Arbutus Biopharma’s earnings last quarter?
Arbutus Biopharma released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma overvalued?
According to Wall Street analysts Arbutus Biopharma’s price is currently Undervalued.
Does Arbutus Biopharma pay dividends?
Arbutus Biopharma does not currently pay dividends.
What is Arbutus Biopharma’s EPS estimate?
Arbutus Biopharma’s EPS estimate is -0.08.
How many shares outstanding does Arbutus Biopharma have?
Arbutus Biopharma has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma’s price movement after its last earnings report?
Arbutus Biopharma reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Arbutus Biopharma?
Among the largest hedge funds holding Arbutus Biopharma’s share is Saba Capital Management. It holds Arbutus Biopharma’s shares valued at 3M.
---
Arbutus Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.75 (44.82% Upside)
$4.75 (44.82% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 233.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
42.47%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
ABUS Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.Read More>---
ABUS Stock 12 Month Forecast
Average Price Target
$4.75
▲(44.82% Upside)
Technical Analysis
ANI Pharmaceuticals
―
Atea Pharmaceuticals
―
BioCryst
―
Durect
―
Forte Biosciences
―
Sangamo Biosciences
―
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
15/32 ratings generated profit
1 Year Average Return
+5.86%
reiterated a buy rating 5 days ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 46.88% of your transactions generating a profit, with an average return of +5.86% per trade.
---